{"entity":{"id":"nct07410676","kind":"trial","name":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors","aka":["EBNK-ST-001"],"tldr":"A phase 1/2 trial of pembrolizumab in pancreatic cancer, run by Essen Biotech, now recruiting.","summary":"EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07410676 by Essen Biotech, with a registry enrolment figure of 83 participants, started 2026-02-01 and due to reach its primary completion in 2028-12-21. Interventions recorded: EBNK-001 + IL-15 + Pembrolizumab. Conditions listed: Cancer; Sarcoma; Leukaemia; Breast Cancer (Locally Advanced or Metastatic); Lung Cancer (Diagnosis); Colorectal Cancer; Melanoma (Skin Cancer); Bladder Cancer; Kidney Cancer; Pancreatic Cancer Metastatic; Liver Cancer (Primary and Metastatic); Ovarian Cancer; Esophageal Cancer; Glioblastoma; Non-Melanoma Skin Cancer. Primary outcome: Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); Incidence of Dose-Limiting Toxicities (DLTs). Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07410676","url":"https://clinicaltrials.gov/study/NCT07410676"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07410676","phase":"1/2","setting":"An Open-Label Phase 1/2 Study of EBNK-001, an Allogeneic Natural Killer (NK) Cell Therapy Administered After Cyclophosphamide/Fludarabine Lymphodepletion With Low-Dose Interleukin-15, With or Without Pembrolizumab, in Participants With Advanced Solid Tumors","sponsor":"Essen Biotech","enrolled":83,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07410676/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}